AI Breast Cancer Risk Assessment: New Tools and Treatments Explained

By Emily Carter | Health & Science Correspondent

Publication date: October 28, 2026

AI breast cancer risk assessment is changing how doctors discuss screening and prevention. At the same time, new FDA-approved breast cancer treatments are expanding options for some patients. These advances come as breast cancer diagnoses continue to rise among U.S. women.

Each development serves a different purpose. Artificial intelligence estimates future cancer risk. Mammograms help detect possible cancer, while targeted medicines treat specific types of breast cancer.

However, new technology does not guarantee early detection or better outcomes for everyone. Women still need screening plans and treatment decisions based on their personal health, medical history and clinical evidence.

How Clairity AI estimates breast cancer risk

The U.S. Food and Drug Administration granted De Novo authorization to Clairity’s Allix5 software on May 30, 2025. The product, known as Clairity Breast, uses screening mammograms to estimate a woman’s five-year breast cancer risk.

Traditional risk assessments often consider age, family history and other known risk factors. By contrast, Clairity analyzes features in mammogram images. The software then produces an estimate of the chance of a breast cancer diagnosis within five years.

This is a risk prediction tool, not a cancer detector. It does not diagnose breast cancer or replace a radiologist’s review of a mammogram. It also does not provide a woman’s lifetime risk.

For example, a five-year risk estimate describes the likelihood of a diagnosis during that period. It does not mean a woman will definitely develop cancer. Likewise, a higher score does not confirm that cancer is already present.

Doctors may use AI breast cancer risk assessment to support conversations about screening and prevention. Depending on a woman’s overall risk, a clinician might discuss additional imaging or genetic counseling. However, an AI score should not make these decisions on its own.

Researchers and clinicians must also consider how well AI tools perform across different populations. Image quality, access, cost and clinical validation matter, too. Therefore, women should ask how a risk result would affect their care before making screening decisions.

Does NCCN recommend breast screening at age 35?

The National Comprehensive Cancer Network updated its breast cancer screening guidance in 2026. The guidance supports earlier screening for certain people at increased risk of invasive breast cancer. This includes some individuals whose five-year risk reaches at least 1.7% under applicable risk assessment methods.

For eligible higher-risk individuals, screening may begin at age 35. The plan can include annual mammography and, in some cases, breast MRI. Clinicians may also recommend regular risk reviews and discussions about risk reduction.

However, this recommendation does not apply to every woman. The age-35 guidance concerns selected higher-risk individuals, not the general population. An AI risk score also needs to be interpreted within the relevant clinical guidance.

For women at average risk, the American Cancer Society offers a different schedule. Women ages 40 to 44 can choose to begin annual mammograms. Women ages 45 to 54 should have annual screening. At age 55, women can switch to screening every other year or continue annually.

Screening advice can vary among medical organizations. In addition, family history, inherited gene changes, previous chest radiation and personal medical history can affect recommendations. Women should discuss their own risk with a qualified healthcare professional.

Why breast cancer diagnoses are rising among younger women

The American Cancer Society reported a steady rise in U.S. breast cancer incidence between 2012 and 2021. Incidence means the number of new cases diagnosed in a population. It does not measure the number of deaths.

During that period, breast cancer incidence among women increased by about 1% each year. The annual increase reached approximately 1.4% among women younger than 50. For women ages 50 and older, the increase was about 0.7% per year.

These figures describe a historical trend, not a confirmed rate for 2026. Researchers have linked changing incidence patterns to several factors, including changes in reproductive patterns and other risk factors. No single cause explains every case.

Importantly, rising diagnoses do not mean breast cancer deaths are increasing at the same rate. The American Cancer Society reports that breast cancer death rates have fallen substantially since 1989. Screening, improved treatments and other advances have contributed to that decline.

Even so, early detection remains important. Women should follow appropriate screening guidance and seek medical advice about new or persistent breast changes. A recent normal mammogram does not rule out every future cancer.

Inluriyo targets a specific type of advanced breast cancer

New FDA-approved breast cancer treatments increasingly target the biology of individual tumors. One example is imlunestrant, sold under the brand name Inluriyo. The FDA first approved the oral medicine in September 2025.

Inluriyo treats certain adults with advanced or metastatic breast cancer that is estrogen receptor-positive, HER2-negative and carries an ESR1 mutation. The cancer must also have progressed after at least one line of endocrine therapy. An FDA-authorized test must identify the mutation.

ER-positive cancer cells use estrogen signals to support growth. HER2-negative means the tumor does not meet the criteria for HER2-positive disease. Meanwhile, ESR1 mutations can change the estrogen receptor and help cancer resist some hormone treatments.

Inluriyo blocks the estrogen receptor pathway. As a result, it offers an option for a specific group of patients whose disease has progressed despite earlier treatment. It is not a general treatment for every breast cancer subtype.

In September 2026, the FDA also approved Inluriyo with abemaciclib, another targeted cancer medicine, for eligible patients with the same broad tumor characteristics. In a clinical trial subgroup with ESR1-mutated tumors, the combination improved progression-free survival compared with Inluriyo alone.

Progression-free survival measures how long patients live without their cancer worsening. It does not mean the treatment cures cancer. Therefore, doctors must consider tumor testing, previous treatment, possible side effects and a patient’s overall health before recommending it.

Datroway adds another targeted treatment option

Datopotamab deruxtecan, marketed as Datroway, belongs to a class called antibody-drug conjugates. These medicines combine an antibody with a powerful cancer-killing drug. The antibody helps direct the medicine toward cells carrying a particular target.

The approach aims to deliver treatment more selectively. However, antibody-drug conjugates can still harm healthy tissue and cause serious side effects. Patients need careful monitoring during treatment.

The FDA approved Datroway in January 2025 for certain adults with unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer. These patients must have received endocrine-based therapy and chemotherapy for advanced disease.

In May 2026, the FDA approved Datroway for a separate group of adults with unresectable or metastatic triple-negative breast cancer. These patients must not be candidates for PD-1 or PD-L1 inhibitor treatment.

Triple-negative breast cancer lacks estrogen and progesterone receptors and does not meet the criteria for HER2-positive disease. It differs from hormone receptor-positive breast cancer. Consequently, the two Datroway approvals have separate eligibility requirements.

Doctors consider tumor type, previous treatments and other health factors when choosing a medicine. They also discuss potential benefits, risks and alternatives. Approval does not mean Datroway is the best option for every patient with advanced breast cancer.

For readers following recent cancer treatment breakthroughs, these medicines show how treatment is becoming more specific to tumor biology. Still, the right option depends on the evidence and the individual patient.

What these developments mean for women

AI risk assessment, breast cancer screening and targeted treatment work at different stages of care. A higher risk score does not mean cancer is present. Likewise, a normal mammogram cannot remove all future risk.

Women can make screening conversations more useful by asking their healthcare professional a few direct questions:

• What factors affect my personal breast cancer risk?
• When should I start screening, and how often should I have a mammogram?
• Would genetic counseling or additional imaging help in my situation?
• Has an AI risk tool been validated for use in my care?
• If I have breast cancer, which tumor tests could affect my treatment options?
• What benefits, side effects and alternatives should I consider before starting a new medicine?

Access can also affect care. AI tools may not be available in every clinic, and costs may vary. Similarly, targeted medicines can require specialized testing, insurance approval and regular monitoring.

Know the warning signs and seek medical advice

Screening mammography is intended for people who do not have breast cancer symptoms. A new lump, nipple changes, unusual discharge or skin dimpling may require diagnostic assessment. Women should seek medical advice about persistent changes, even after a normal screening mammogram.

These changes do not automatically mean cancer. However, prompt assessment can help a clinician determine whether further testing is needed. Self-examination and general breast awareness do not replace recommended mammography.

Women with a history of breast cancer, inherited gene changes or previous chest radiation may need a personalized screening plan. Others should follow the guidance that best fits their age and risk. A healthcare professional can help explain the options.

New options still require informed decisions

AI breast cancer risk assessment may give doctors another way to discuss future risk. Meanwhile, Inluriyo and Datroway offer treatment options for specific types of advanced breast cancer. These advances can help personalize care, but they do not remove uncertainty.

The next priority is to use each tool where evidence supports it. Women should understand their risk, follow suitable screening guidance and seek assessment for concerning changes. For patients with cancer, treatment choices should reflect tumor biology, prior care and personal needs.

Ultimately, technology works best alongside good medical judgment. Clear conversations between patients and healthcare professionals remain essential for informed screening and treatment decisions.